## AP3 Rec'd PCT/PTO 24 MAR 2008

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ATTORNEY'S DOCKET NUMBER

PRIORITY DATE CLAIMED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INTERNATIONAL FILING DATE

# TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

5178
U.S.ABBLICATION NO. (IRKNO) (IRKN

PCT/US2004/033430 8 October 2004 (08.10.2004) 10 October 2003 (10.10.2003) TITLE OF INVENTION PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS APPLICANT(S) FOR DO/EO/US Julie A. DIXON, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7 🗸 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). **|** An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

An English language translation of the annexes of the International Preliminary Examination Report under PCT

13. A preliminary amendment.

INTERNATIONAL APPLICATION NO.

An Application Data Sheet under 37 CFR 1.76.

Article 36 (35 U.S.C. 371(c)(5)).

15. A substitute specification.

16. A power of attorney and/or change of address letter.

17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.

18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).

19. L.J. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 3

ORIGINAL

### IAP20 REC'S FOTATO 24 MAR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION	NO (iHknown see 37°C FR 1.	) INTERNATIONAL AF	PPLICATION NO.	ATTORNEY'S	DOCKET NUMBER
	2/2/5	PCT/US2004	4/033430		5178
20. Other item	2) Notific	cate of Mailing under 37 C cation(s) of the Recording ed Return Receipt Postcar	of a Change rega	rding inventors, B	EAR, FU, and WANG
The following	g fees have been submitted			CALCULATIONS	PTO USE ONLY
21. 🗾 Basic nat	tional fee (37 CFR 1.492(a)).	• • •	\$300	\$ 300.00	1 335 31.5.
22. 🚺 Examinati	ion fee (37 CFR 1,492(c))		<u> </u>		
If the written opinion p	prepared by ISA/US or the int ndicates all claims satisfy pro	\$ 200.00			
If the written opinion of IPEA/US indic Search fee (37 CFR 1 International Search F previously com	cates all claims satisfy provis 1.445(a)(2)) has been paid on Searching AuthorityReport prepared by an ISA other ISA other of the US by the	onal preliminary examination repons of PCT Article 33(1)-(4) the international application to the rethan the US and provided to B.		\$ 500.00	
TOTAL OF 21, 22 and 23 =				\$1,000.00	
sequence listi electronic med The fee is \$25	specification and drawings filing in compliance with 37 CFdium) (37 CFR 1.492(j)). 60 for each additional 50 sheet  The sheets Number of each thereof (round)				
275 - 100 = 1	175 /50 =	4	x \$250	\$ 1,000.00	1
Surcharge of \$130.00 after the date of comm	for fumishing any of the sear nencement of the national sta	ch fee, examination fee, or the ge (37 CFR 1.492(h)).	oath or declaration	\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	11 - 20 =	0	x \$ 50	\$ 00.00	
Independent claims	4 - 3 =	1	x \$200	\$ 200.00	
MULTIPLE DEPENDE	NT CLAIM(S) (if applicable)	\$ 00.00			
- AP		\$ 2,200.00			
Applicant claims s	small entity status. See 37 CF	R 1.27. Fees above are reduce	ed by ½.  SUBTOTAL =		
Dragoning for of \$420	0.00 ((	\$ 2,200.00			
claimed priority date (3		translation later than 30 month	ns from the earliest +	\$	
		\$ 2,200.00			
Fee for recording the e by an appropriate cover	enclosed assignment (37 CFF er sheet (37 CFR 3.28, 3.31).	R 1.21(h)). The assignment mus \$40.00 per property	t be accompanied +	\$	
		\$ 2,200.00			
				Amount to be refunded:	\$
				Amount to be charged	\$

10/573227

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. 🗌 Act	heck in the amount of \$ to coverage	P20Rec': 1257/PTO 24 MAR 2006			
b. Plea A du	ase charge my Deposit Account No <b>13-3372</b> _ in the amour uplicate copy of this sheet is enclosed.	nt of \$ 2,200.00 to cover the above fees.			
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372. A duplicate copy of this sheet is enclosed.					
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
Jeffrey Vice P Patent Bayer 400 Mo	PRRESPONDENCE TO: Customer No. 35969  By M. Greenman  President Its and Licensing Pharmaceuticals Corporaton  Horgan Lane  Haven, CT 06516	SIGNATURE William F. Gray NAME 31,018 REGISTRATION NUMBER			

Date of Deposit: 24 March 2006 Express Mail Label Number: EQ 409 312 219 US



Attorney's Docket No. 5178

**PATENT** 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Julie A. Dixon, et al.

Serial No.: [to be assigned] National Stage Filing of PCT/US2004/033430

Filed: herewith

For: Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders

MAIL STOP PCT **COMMISSIONER FOR PATENTS** P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450** 

#### **CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that the attached correspondence comprising:

- 1. Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];
- 2. Application Data Sheet under 37 C.F.R. 1.76;
- 3. Copies of Notifications of the Recording of Changes regarding inventors BEAR, FU, and WANG;
- 4. Declaration of the inventor(s) (35 U.S.C. 371(c)(4));
- Copy of the International Application as filed (35 U.S.C. 371(c)(2));
- Itemized Return Receipt Post Card.

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number \_\_\_\_\_EQ 409 312 219 US addressed to:

> Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

24 March 2006 Date

Signature of Person Certifying / Beatriz Alviz